NASDAQ:AMGN - Amgen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $242.57
  • Forecasted Upside: -1.55 %
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$246.40
▼ -0.33 (-0.13%)

This chart shows the closing price for AMGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMGN

Analyst Price Target is $242.57
▼ -1.55% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $242.57, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -1.55% upside from the last price of $246.40.

This chart shows the closing price for AMGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 14 contributing investment analysts is to hold stock in Amgen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 16 hold ratings
  • 1 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 14 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 13 hold ratings
  • 2 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 12 hold ratings
  • 2 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 2 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 11 hold ratings
  • 2 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 1 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 1 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/24/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00Low
6/1/2022OppenheimerBoost Price TargetOutperform$285.00 ➝ $290.00Medium
5/23/2022SVB LeerinkInitiated CoverageMarket Perform$256.00Low
5/10/2022MizuhoBoost Price Target$202.00 ➝ $208.00Low
5/3/2022OppenheimerDowngradeOutperform$285.00Low
4/28/2022BMO Capital MarketsLower Price Target$263.00 ➝ $243.00Low
4/28/2022Piper SandlerBoost Price Target$255.00 ➝ $260.00High
4/12/2022Morgan StanleyLower Price TargetEqual Weight$238.00 ➝ $237.00Low
4/12/2022BarclaysBoost Price TargetEqual Weight$233.00 ➝ $236.00Low
3/1/2022MizuhoBoost Price Target$194.00 ➝ $202.00Low
2/9/2022Morgan StanleyBoost Price TargetEqual Weight$235.00 ➝ $238.00Low
2/9/2022Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$266.00 ➝ $280.00Low
2/9/2022OppenheimerBoost Price TargetOutperform$272.00 ➝ $285.00Medium
2/9/2022BarclaysBoost Price TargetEqual Weight$228.00 ➝ $233.00Medium
2/9/2022Wells Fargo & CompanyBoost Price TargetEqual Weight$210.00 ➝ $250.00Medium
1/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$285.00 ➝ $255.00Low
12/21/2021Royal Bank of CanadaBoost Price TargetSector Perform$216.00 ➝ $218.00Low
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$213.00 ➝ $210.00Low
12/6/2021The Goldman Sachs GroupInitiated CoverageBuy$258.00High
11/22/2021MizuhoLower Price TargetNeutral$222.00 ➝ $194.00Medium
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$228.00Low
11/3/2021Royal Bank of CanadaLower Price TargetSector Perform$217.00 ➝ $216.00High
11/3/2021SVB LeerinkLower Price TargetMarket Perform$234.00 ➝ $216.00High
11/3/2021BarclaysLower Price TargetEqual Weight$230.00 ➝ $228.00High
11/1/2021OppenheimerLower Price TargetOutperform$277.00 ➝ $272.00Medium
10/28/2021Robert W. BairdReiterated RatingSellLow
10/12/2021Morgan StanleyLower Price TargetEqual Weight$251.00 ➝ $235.00High
9/23/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$220.00Low
9/19/2021SVB LeerinkInitiated CoverageHoldMedium
9/17/2021William BlairReiterated RatingHoldHigh
9/10/2021MizuhoInitiated CoverageHold$222.00Low
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$280.00 ➝ $251.00High
8/5/2021Robert W. BairdReiterated RatingSellHigh
8/4/2021SVB LeerinkLower Price TargetMarket Perform$238.00 ➝ $234.00High
7/28/2021Robert W. BairdReiterated RatingSell$185.00Low
7/16/2021Morgan StanleyBoost Price TargetOverweight$278.00 ➝ $280.00Medium
6/25/2021MizuhoReiterated RatingHold$200.00Medium
6/7/2021SVB LeerinkBoost Price TargetMarket Perform$230.00 ➝ $238.00Low
6/7/2021OppenheimerBoost Price TargetOutperform$272.00 ➝ $277.00Low
5/31/2021BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$296.00 ➝ $301.00High
5/17/2021OppenheimerReiterated RatingBuy$270.00Low
5/4/2021Atlantic SecuritiesReiterated RatingNeutral ➝ Underweight$200.00N/A
5/3/2021OppenheimerLower Price TargetOutperform$275.00 ➝ $265.00Low
4/29/2021Robert W. BairdReiterated RatingSellMedium
4/29/2021Evercore ISIReiterated RatingBuyMedium
4/28/2021Atlantic SecuritiesDowngradeNeutral ➝ Underweight$200.00Low
4/28/2021Credit Suisse GroupLower Price TargetOutperform$265.00 ➝ $259.00High
4/28/2021SVB LeerinkLower Price TargetMarket Perform$267.00 ➝ $230.00High
4/28/2021Royal Bank of CanadaLower Price TargetSector Perform$220.00 ➝ $217.00High
4/28/2021JPMorgan Chase & Co.Reiterated RatingNeutral$215.00High
4/28/2021The Goldman Sachs GroupReiterated RatingBuy$290.00High
4/28/2021BMO Capital MarketsLower Price TargetOutperform$301.00 ➝ $296.00High
4/26/2021Morgan StanleyLower Price TargetOverweight$281.00 ➝ $278.00Low
4/19/2021Morgan StanleyBoost Price TargetOverweight$279.00 ➝ $281.00Low
4/5/2021OppenheimerBoost Price Target$266.00 ➝ $275.00Low
3/5/2021BarclaysLower Price TargetEqual Weight$242.00 ➝ $230.00High
3/5/2021Morgan StanleyBoost Price TargetOverweight$277.00 ➝ $279.00High
3/4/2021JPMorgan Chase & Co.Set Price TargetNeutral$222.00High
3/4/2021The Goldman Sachs GroupSet Price TargetBuy$277.00High
3/1/2021SVB LeerinkBoost Price TargetMarket Perform$252.00 ➝ $260.00Low
2/3/2021Morgan StanleyLower Price TargetOverweight$285.00 ➝ $277.00Medium
2/3/2021Credit Suisse GroupLower Price TargetOutperform$280.00 ➝ $265.00Medium
2/3/2021SVB LeerinkLower Price TargetMarket Perform$253.00 ➝ $245.00Medium
2/3/2021Piper SandlerLower Price TargetOverweight$280.00 ➝ $260.00Medium
2/3/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$280.00 ➝ $295.00Low
1/31/2021OppenheimerReiterated RatingBuy$266.00Low
1/19/2021Morgan StanleyBoost Price TargetOverweight$276.00 ➝ $285.00Low
1/4/2021Royal Bank of CanadaReiterated RatingNeutralN/A
12/29/2020Daiwa Capital MarketsInitiated CoverageBuy$300.00 ➝ $300.00N/A
12/29/2020Royal Bank of CanadaReiterated RatingNeutralN/A
12/27/2020OppenheimerInitiated CoveragePositive ➝ Buy$274.00 ➝ $266.00N/A
12/27/2020JPMorgan Chase & Co.Reiterated RatingHoldN/A
12/23/2020Royal Bank of CanadaReiterated RatingNeutralN/A
12/16/2020Morgan StanleyBoost Price TargetOverweight$275.00 ➝ $276.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/9/2020SVB LeerinkBoost Price TargetMarket Perform$243.00 ➝ $253.00Low
12/8/2020Piper SandlerBoost Price TargetOverweight$270.00 ➝ $280.00Low
11/16/2020OppenheimerLower Price TargetOutperform$280.00 ➝ $274.00Low
11/11/2020OppenheimerInitiated CoveragePositive ➝ Buy$275.00 ➝ $280.00Low
11/2/2020MizuhoLower Price TargetNeutral$260.00 ➝ $215.00Low
10/29/2020Cantor FitzgeraldLower Price TargetOverweight$279.00 ➝ $278.00Low
10/29/2020BMO Capital MarketsLower Price TargetOutperform$308.00 ➝ $304.00Low
10/29/2020JPMorgan Chase & Co.Lower Price TargetNeutral$232.00 ➝ $222.00Medium
10/29/2020SVB LeerinkLower Price TargetMarket Perform$261.00 ➝ $243.00Medium
10/29/2020Bank of AmericaLower Price TargetBuy$275.00 ➝ $265.00Medium
10/29/2020Morgan StanleyBoost Price TargetMarket Perform ➝ Overweight$273.00 ➝ $275.00Medium
10/29/2020BarclaysLower Price TargetEqual Weight$250.00 ➝ $242.00Low
10/28/2020UBS GroupInitiated CoverageNeutral$232.00High
10/27/2020Credit Suisse GroupLower Price TargetOutperform$286.00 ➝ $284.00Low
10/26/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$255.00Medium
10/22/2020OppenheimerLower Price TargetOutperform$280.00 ➝ $275.00Low
10/15/2020Royal Bank of CanadaReiterated RatingHold$223.00Medium
10/13/2020Morgan StanleyLower Price TargetOverweight$281.00 ➝ $273.00Low
10/12/2020Truist FinancialUpgradeHold ➝ BuyLow
10/9/2020Truist FinancialDowngradeBuy ➝ Hold$251.00Medium
10/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market PerformMedium
10/6/2020Raymond JamesReiterated RatingOutperform ➝ Market PerformMedium
10/6/2020OppenheimerBoost Price TargetPositive ➝ Outperform$270.00 ➝ $280.00Medium
9/23/2020William BlairReiterated RatingHoldMedium
9/22/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
9/21/2020OppenheimerReiterated RatingBuy$270.00Medium
7/30/2020SunTrust BanksBoost Price TargetBuy$254.00 ➝ $268.00Low
7/29/2020Credit Suisse GroupReiterated RatingBuyLow
7/29/2020Wells Fargo & CompanyBoost Price TargetEqual Weight ➝ In-Line$237.00 ➝ $247.00Low
7/29/2020Jefferies Financial GroupBoost Price TargetBuy$285.00 ➝ $300.00Low
7/29/2020Royal Bank of CanadaLower Price TargetSector Perform$236.00 ➝ $223.00High
7/29/2020Morgan StanleyLower Price TargetOverweight$285.00 ➝ $281.00Medium
7/29/2020SVB LeerinkBoost Price TargetMarket Perform$253.00 ➝ $261.00Medium
7/29/2020Cantor FitzgeraldBoost Price TargetOverweight$263.00 ➝ $279.00Medium
7/29/2020BarclaysBoost Price TargetEqual Weight$245.00 ➝ $250.00Medium
7/28/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$255.00 ➝ $270.00Medium
7/28/2020JPMorgan Chase & Co.Boost Price TargetNeutral$225.00 ➝ $232.00Medium
7/20/2020OppenheimerBoost Price TargetOutperform$252.00 ➝ $265.00Low
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$252.00 ➝ $290.00Low
7/15/2020Morgan StanleyBoost Price TargetOverweight$280.00 ➝ $285.00Low
6/18/2020JPMorgan Chase & Co.Boost Price TargetNeutral$219.00 ➝ $225.00Medium
6/2/2020SVB LeerinkBoost Price TargetMarket Perform$249.00 ➝ $253.00High
5/4/2020Cantor FitzgeraldBoost Price TargetOverweight$255.00 ➝ $263.00Low
5/1/2020CfraBoost Price TargetBuy$223.00 ➝ $259.00Low
5/1/2020Bank of AmericaBoost Price TargetBuy$250.00 ➝ $265.00High
5/1/2020SVB LeerinkBoost Price TargetMarket Perform$219.00 ➝ $249.00High
5/1/2020Morgan StanleyBoost Price TargetOverweight$267.00 ➝ $280.00High
5/1/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$274.00 ➝ $291.00High
5/1/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$220.00 ➝ $237.00High
5/1/2020OppenheimerInitiated CoverageBuy$252.00Medium
4/30/2020MizuhoReiterated RatingHold$215.00Medium
4/30/2020Piper SandlerBoost Price TargetOverweight$235.00 ➝ $255.00Medium
4/26/2020OppenheimerBoost Price TargetOutperform$240.00 ➝ $250.00Medium
4/15/2020Morgan StanleyLower Price TargetOverweight$277.00 ➝ $267.00Low
4/15/2020GuggenheimInitiated CoverageNeutral$225.00Low
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$218.00Medium
3/29/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$255.00High
3/26/2020OppenheimerLower Price TargetOutperform$250.00 ➝ $240.00High
3/13/2020CfraUpgradeHold ➝ BuyHigh
3/9/2020OppenheimerLower Price Target$256.00 ➝ $250.00Medium
3/5/2020Bank of AmericaUpgradeNeutral ➝ Buy$245.00 ➝ $250.00Medium
2/27/2020BarclaysInitiated CoverageEqual Weight$235.00High
2/6/2020ArgusReiterated RatingBuy$265.00 ➝ $265.00Low
2/3/2020SunTrust BanksBoost Price TargetBuy ➝ Buy$254.00 ➝ $265.00Low
2/2/2020Credit Suisse GroupReiterated RatingBuy$252.00Low
2/2/2020JPMorgan Chase & Co.Reiterated RatingNeutral ➝ HoldLow
1/31/2020CfraBoost Price TargetHold$215.00 ➝ $223.00High
1/31/2020CowenReiterated RatingBuyHigh
1/31/2020Robert W. BairdDowngradeNeutral ➝ Underperform$173.00 ➝ $185.00High
1/30/2020MizuhoReiterated RatingHold$215.00High
1/24/2020JPMorgan Chase & Co.Set Price TargetNeutral$198.00Low
1/23/2020CitigroupBoost Price TargetBuy ➝ In-Line$245.00 ➝ $275.00Low
1/22/2020UBS GroupBoost Price TargetNeutral$194.00 ➝ $238.00Low
1/21/2020OppenheimerBoost Price Target$250.00 ➝ $260.00Low
1/21/2020Evercore ISIUpgradeIn-Line ➝ OutperformMedium
1/19/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
1/17/2020Morgan StanleyLower Price TargetOverweight$280.00 ➝ $277.00Low
1/14/2020Cantor FitzgeraldReiterated RatingBuy$255.00Low
1/9/2020BMO Capital MarketsBoost Price TargetOutperform$240.00 ➝ $275.00Low
12/23/2019Raymond JamesInitiated CoverageMarket PerformN/A
12/19/2019CowenBoost Price TargetOutperform$253.00 ➝ $277.00Medium
12/17/2019Morgan StanleyInitiated CoverageOverweight$280.00Low
12/13/2019Credit Suisse GroupBoost Price TargetOutperform$235.00 ➝ $250.00Medium
12/9/2019ArgusBoost Price TargetPositive ➝ Buy$240.00 ➝ $265.00Low
11/12/2019SunTrust BanksInitiated CoverageBuy$256.00Low
11/5/2019Cantor FitzgeraldUpgradeNeutral ➝ Overweight$230.00 ➝ $255.00Low
10/30/2019SVB LeerinkBoost Price TargetMarket Perform$189.00 ➝ $205.00High
10/16/2019Bank of AmericaInitiated CoverageNeutral$215.00Low
10/14/2019Sanford C. BernsteinInitiated CoverageOutperformLow
9/30/2019JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/30/2019The Goldman Sachs GroupSet Price TargetBuy$243.00Medium
9/30/2019BMO Capital MarketsSet Price TargetBuy$240.00Medium
9/30/2019Cantor FitzgeraldSet Price TargetHold$230.00Medium
9/30/2019SVB LeerinkSet Price TargetHold$189.00Medium
9/30/2019Royal Bank of CanadaReiterated RatingHoldMedium
9/29/2019CowenSet Price TargetBuy$231.00Medium
9/29/2019MizuhoReiterated RatingHold$212.00Medium
9/12/2019SVB LeerinkReiterated RatingHoldLow
9/9/2019BMO Capital MarketsReiterated RatingBuyHigh
9/9/2019OppenheimerSet Price TargetBuy$240.00High
9/6/2019JPMorgan Chase & Co.Set Price TargetHold$198.00High
9/5/2019Cantor FitzgeraldReiterated RatingNeutral$221.00 ➝ $230.00Low
8/30/2019William BlairReiterated RatingHoldMedium
8/29/2019JPMorgan Chase & Co.Boost Price TargetNeutral$191.00 ➝ $198.00Low
8/27/2019OppenheimerBoost Price Target$230.00 ➝ $240.00Low
8/27/2019BMO Capital MarketsBoost Price TargetOutperform$230.00 ➝ $240.00Low
8/27/2019JPMorgan Chase & Co.Reiterated RatingHold$191.00 ➝ $198.00Low
8/27/2019Wells Fargo & CompanyReiterated RatingMarket Perform$202.00 ➝ $220.00Low
8/27/2019Royal Bank of CanadaBoost Price TargetSector Perform$192.00 ➝ $206.00Low
8/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$210.00 ➝ $218.00Low
8/22/2019CowenSet Price TargetBuy$231.00Low
8/21/2019Royal Bank of CanadaBoost Price TargetSector Perform$192.00Low
8/19/2019MizuhoDowngradeBuy ➝ Neutral$208.00 ➝ $212.00Low
8/16/2019Credit Suisse GroupReiterated RatingOutperform$202.00 ➝ $225.00Low
8/13/2019OppenheimerBoost Price TargetOutperform$210.00 ➝ $230.00Medium
8/12/2019CitigroupReiterated RatingBuyLow
8/12/2019Credit Suisse GroupSet Price TargetBuy$202.00Low
8/12/2019Wells Fargo & CompanyBoost Price TargetMarket Perform ➝ Market Perform$197.00 ➝ $202.00High
8/11/2019Evercore ISIReiterated RatingHoldHigh
8/11/2019Royal Bank of CanadaReiterated RatingHoldHigh
8/10/2019Piper Jaffray CompaniesSet Price TargetBuy$210.00Low
8/9/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
7/31/2019BMO Capital MarketsSet Price TargetBuy$230.00Low
7/15/2019Morgan StanleyLower Price TargetOverweight$211.00 ➝ $207.00Low
7/1/2019MizuhoReiterated RatingBuy$208.00Low
6/24/2019MizuhoReiterated RatingBuy$208.00Low
5/24/2019OppenheimerSet Price TargetBuy$210.00Medium
5/22/2019CitigroupUpgradeNeutral ➝ Buy$211.00 ➝ $205.00Low
5/21/2019Royal Bank of CanadaReiterated RatingNeutral$192.00Low
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$208.00 ➝ $208.00Low
5/17/2019MizuhoReiterated RatingBuy$208.00Low
5/15/2019JPMorgan Chase & Co.Reiterated RatingHold$190.00Medium
5/10/2019MizuhoSet Price TargetBuy$208.00High
5/1/2019CowenReiterated RatingBuy$229.00High
4/22/2019MizuhoSet Price TargetBuy$208.00Low
4/12/2019MizuhoSet Price TargetBuy$208.00Low
4/1/2019Cantor FitzgeraldReiterated RatingHold$221.00Low
3/22/2019MizuhoSet Price TargetBuy$208.00Low
3/14/2019BMO Capital MarketsInitiated CoverageOutperform$228.00High
2/26/2019MizuhoReiterated RatingBuy$211.00Low
2/26/2019CowenReiterated RatingBuy$234.00Low
2/13/2019MizuhoReiterated RatingBuy$211.00Low
2/1/2019Royal Bank of CanadaReiterated RatingNeutralLow
1/30/2019SVB LeerinkLower Price TargetMarket Perform$200.00 ➝ $192.00High
1/30/2019JPMorgan Chase & Co.Reiterated RatingNeutral$190.00High
1/27/2019OppenheimerSet Price TargetBuy$224.00High
1/17/2019The Goldman Sachs GroupReiterated RatingBuy$232.00Low
1/14/2019Royal Bank of CanadaReiterated RatingNeutral$182.00Low
1/4/2019CitigroupBoost Price TargetNeutral ➝ Neutral$204.00 ➝ $210.00Low
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$213.00 ➝ $212.00Medium
12/10/2018The Goldman Sachs GroupSet Price TargetBuy$232.00Low
12/4/2018Jefferies Financial GroupReiterated RatingBuy$220.00Medium
12/4/2018BarclaysReiterated RatingNeutral$195.00Medium
12/4/2018Cantor FitzgeraldReiterated RatingNeutral$223.00Medium
12/4/2018JPMorgan Chase & Co.Set Price TargetNeutral$192.00Medium
12/4/2018Royal Bank of CanadaReiterated RatingNeutral$182.00Medium
12/4/2018Morgan StanleyReiterated RatingBuy$213.00Medium
12/4/2018The Goldman Sachs GroupReiterated RatingBuy$232.00Medium
11/1/2018Royal Bank of CanadaReiterated RatingNeutralLow
11/1/2018CitigroupBoost Price TargetNeutral ➝ Neutral$200.00 ➝ $204.00Low
10/31/2018The Goldman Sachs GroupReiterated RatingBuy$221.00Low
10/31/2018Morgan StanleyBoost Price TargetOverweight ➝ Buy$212.00 ➝ $213.00Low
10/31/2018Royal Bank of CanadaLower Price TargetMarket Perform$182.00Low
10/31/2018Cantor FitzgeraldReiterated RatingHold$223.00Medium
10/30/2018OppenheimerSet Price TargetBuy$224.00Medium
10/26/2018MizuhoReiterated RatingBuy$206.00Low
10/25/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/12/2018The Goldman Sachs GroupReiterated RatingBuy$229.00Low
10/11/2018Morgan StanleyBoost Price TargetOverweight$210.00 ➝ $212.00Low
10/9/2018JPMorgan Chase & Co.Set Price TargetNeutral$192.00Low
10/8/2018Cantor FitzgeraldSet Price TargetNeutral$223.00Low
10/8/2018Jefferies Financial GroupSet Price TargetBuy$220.00Low
10/2/2018OppenheimerReiterated RatingBuy$224.00Low
10/1/2018Jefferies Financial GroupReiterated RatingBuy$220.00Medium
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$223.00Low
9/28/2018Royal Bank of CanadaSet Price TargetNeutral$193.00Low
9/17/2018SVB LeerinkSet Price TargetHold$209.00Low
9/12/2018Jefferies Financial GroupSet Price TargetBuy$220.00Low
9/10/2018OppenheimerSet Price TargetBuy$224.00High
9/10/2018Royal Bank of CanadaReiterated RatingNeutral$193.00High
9/6/2018Jefferies Financial GroupSet Price TargetBuy$220.00Low
8/29/2018Wells Fargo & CompanyReiterated RatingNeutral$197.00Medium
8/28/2018OppenheimerReiterated RatingBuy$224.00Low
8/24/2018Jefferies Financial GroupReiterated RatingBuy$220.00Low
7/30/2018MorningstarSet Price TargetNeutral$198.00Low
7/30/2018Wells Fargo & CompanyReiterated RatingNeutral$197.00Low
7/30/2018OppenheimerReiterated RatingBuy$224.00Low
7/30/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$165.00 ➝ $179.00Low
7/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$188.00 ➝ $200.00Low
7/27/2018MizuhoReiterated RatingBuy$200.00Low
7/27/2018The Goldman Sachs GroupReiterated RatingBuy$228.00Low
7/27/2018Royal Bank of CanadaSet Price TargetBuy$193.00Low
7/27/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$200.00 ➝ $220.00High
7/27/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$191.00 ➝ $192.00High
7/26/2018Piper Jaffray CompaniesBoost Price TargetIn-Line ➝ Overweight$190.00 ➝ $210.00High
7/16/2018Jefferies Financial GroupReiterated RatingBuy$200.00Low
7/13/2018Morgan StanleyBoost Price TargetBuy$200.00 ➝ $210.00Low
6/22/2018MizuhoReiterated RatingBuy$200.00Low
5/15/2018MizuhoSet Price TargetBuy$200.00High
4/25/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$205.00 ➝ $200.00Medium
4/25/2018Royal Bank of CanadaLower Price TargetSector Perform$183.00High
4/24/2018MizuhoSet Price TargetBuy$200.00High
4/24/2018CowenReiterated RatingBuy$204.00Medium
4/5/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$190.00 ➝ $180.00Low
2/12/2018MizuhoBoost Price TargetBuy ➝ Buy$192.00 ➝ $200.00Low
2/5/2018Atlantic SecuritiesDowngradeOverweight ➝ Neutral$187.01High
2/4/2018JPMorgan Chase & Co.Reiterated RatingHold$191.00High
2/2/2018SVB LeerinkReiterated RatingMarket PerformHigh
2/2/2018CowenReiterated RatingBuy$204.00Low
2/2/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$191.00 ➝ $194.00Low
2/2/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$192.00 ➝ $202.00Medium
2/2/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$204.00 ➝ $196.00Medium
2/2/2018Piper Jaffray CompaniesLower Price TargetOverweight ➝ Overweight$194.00 ➝ $190.00Medium
2/1/2018MizuhoReiterated RatingBuy$192.00High
1/30/2018OppenheimerReiterated RatingBuy$205.00 ➝ $205.00Low
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$184.00 ➝ $189.00Low
1/24/2018Royal Bank of CanadaReiterated RatingHold$189.00Low
1/23/2018ArgusUpgradeHold ➝ Buy$192.33 ➝ $220.00Low
1/5/2018OppenheimerSet Price TargetBuy$205.00Low
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyLow
12/28/2017MizuhoSet Price TargetBuy$192.00Low
12/22/2017MizuhoSet Price TargetBuy$192.00Low
12/18/2017CitigroupDowngradeNeutralLow
12/15/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
12/12/2017OppenheimerSet Price TargetBuy$205.00Low
11/30/2017OppenheimerReiterated RatingBuy$205.00Low
11/1/2017ArgusDowngradeBuy ➝ Hold$175.22 ➝ $195.00N/A
10/29/2017MizuhoSet Price TargetBuy$198.00N/A
10/26/2017BMO Capital MarketsReiterated RatingMarket Perform$198.00N/A
10/26/2017Morgan StanleyLower Price TargetOverweight$196.00 ➝ $193.00N/A
10/26/2017Royal Bank of CanadaLower Price TargetSector Perform$192.00 ➝ $188.00N/A
10/20/2017BMO Capital MarketsReiterated RatingHold$198.00N/A
10/13/2017BarclaysBoost Price TargetEqual Weight$180.00 ➝ $190.00N/A
10/6/2017OppenheimerReiterated RatingBuy$203.00N/A
10/6/2017MizuhoReiterated RatingBuy$198.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$189.00 ➝ $196.00N/A
10/5/2017Bank of AmericaBoost Price TargetBuy$210.00N/A
9/29/2017Credit Suisse GroupReiterated RatingNeutral$177.00 ➝ $186.00Medium
9/28/2017MizuhoReiterated RatingBuy ➝ Buy$183.00 ➝ $198.00Low
9/25/2017Jefferies Financial GroupReiterated RatingBuy$200.00Low
9/25/2017BMO Capital MarketsReiterated RatingHold$199.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$192.00High
9/7/2017OppenheimerReiterated RatingBuy$203.00Low
8/21/2017MizuhoReiterated RatingBuy$195.00 ➝ $183.00Low
7/27/2017ArgusBoost Price TargetBuy$180.00 ➝ $195.00Low
7/26/2017UBS GroupSet Price TargetHold$175.00 ➝ $180.00High
7/26/2017OppenheimerReiterated RatingOutperform$189.00 ➝ $203.00Low
7/26/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$172.00 ➝ $174.00Low
7/26/2017BMO Capital MarketsDowngradeOutperform ➝ Market PerformLow
7/22/2017CowenReiterated RatingOutperform$209.00Low
7/21/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$199.00Low
7/17/2017Jefferies Financial GroupReiterated RatingBuy$195.00Low
7/14/2017Credit Suisse GroupSet Price TargetHold$177.00Low
7/14/2017OppenheimerReiterated RatingOutperform$189.00Low
7/11/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$195.00Low
7/10/2017Morgan StanleyReiterated RatingOverweightLow
7/9/2017MizuhoReiterated RatingBuy$195.00Low
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 41 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
12/8/2021
  • 9 very positive mentions
  • 43 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
1/7/2022
  • 14 very positive mentions
  • 40 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
2/6/2022
  • 19 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
3/8/2022
  • 9 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
4/7/2022
  • 12 very positive mentions
  • 45 positive mentions
  • 3 negative mentions
  • 6 very negative mentions
5/7/2022
  • 13 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/6/2022
  • 9 very positive mentions
  • 28 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
7/6/2022

Current Sentiment

  • 9 very positive mentions
  • 28 positive mentions
  • 7 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $246.40
Low: $245.88
High: $248.06

50 Day Range

MA: $243.16
Low: $230.71
High: $256.74

52 Week Range

Now: $246.40
Low: $198.64
High: $258.45

Volume

40,114 shs

Average Volume

3,391,541 shs

Market Capitalization

$131.63 billion

P/E Ratio

24.28

Dividend Yield

3.16%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Amgen?

The following Wall Street research analysts have issued reports on Amgen in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Daiwa Capital Markets, Jefferies Financial Group Inc., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for AMGN.

What is the current price target for Amgen?

0 Wall Street analysts have set twelve-month price targets for Amgen in the last year. Their average twelve-month price target is $242.57, suggesting a possible downside of 1.7%.
View the latest price targets for AMGN.

What is the current consensus analyst rating for Amgen?

Amgen currently has 1 sell rating, 10 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMGN, but not buy more shares or sell existing shares.
View the latest ratings for AMGN.

How do I contact Amgen's investor relations team?

Amgen's physical mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company's listed phone number is (805) 447-1000 and its investor relations email address is [email protected] The official website for Amgen is www.amgen.com. Learn More about contacing Amgen investor relations.